Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease

This publication has 26 references indexed in Scilit:

• Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies
  American Heart Journal, 2003
• Prolonged Anti-Factor Xa Level in a Patient with Moderate Renal Insufficiency Receiving Enoxaparin
  American Journal of Nephrology, 2002
• Safety Profile of Tinzaparin Administered Once Daily at a Standard Curative Dose in Two Hundred Very Elderly Patients
  Drug Safety, 2002
• Spontaneous Hemomediastinum Complicating Steroid-Induced Mediastinal Lipomatosis
  Chest, 2001
• Excessive anticoagulation in patients with mild renal insufficiency receiving long‐term therapeutic enoxaparin
  American Journal of Hematology, 2001
• Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction
  Circulation, 1999
• Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis
  Annals of Internal Medicine, 1999
• A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
  New England Journal of Medicine, 1997
• Low Molecular Weight Heparins
  Drugs & Aging, 1992
• Delayed elimination of enoxaparine in patients with chronic renal insufficiency
  Thrombosis Research, 1991